NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
Clinical Trials
53 trialsNCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05910970 2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3 Unknown
NCT06192784 2024-01-09
CCGLC-012
Tongji Hospital
Phase 2 Unknown
NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
NCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05823987 2023-06-27
OPTIONS-05
Fudan University
Phase 2 Unknown
NCT05893056 2023-06-27
CASTLE-09
Fudan University
Phase 2 Unknown
NCT05903456 2023-06-15
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05889949 2023-06-07
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT04967495 2023-05-18
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Unknown
NCT04211168 2023-03-29
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04368078 2023-03-29
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05781074 2023-03-24
CASTLE-08
Fudan University
Phase 2 Unknown
NCT05675462 2023-03-06
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Phase 1 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT05410197 2022-10-12
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
Sun Yat-sen University
Phase 2 Unknown
NCT05509478 2022-09-10
LEADER-001
The First Hospital of Jilin University
Phase 2 Unknown
NCT05036798 2022-09-07
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05391867 2022-05-26
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
Phase NA Unknown
NCT05220020 2022-05-19
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT05291052 2022-03-22
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05221775 2022-02-03
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT05162898 2022-01-27
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
Henan Cancer Hospital
Phase NA Unknown
NCT05171530 2021-12-29
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04443049 2021-10-05
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
Institute of Liver and Biliary Sciences, India
Phase NA Unknown
NCT04490694 2021-09-24
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05056337 2021-09-24
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Shanghai Zhongshan Hospital
Phase 3 Unknown
NCT04531228 2021-09-22
Thalen
Sun Yat-sen University
Phase NA Unknown
NCT04814043 2021-09-22
PLATIC
Sun Yat-sen University
Phase 2 Unknown
NCT05007587 2021-08-16
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Zhejiang Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT04127396 2021-07-23
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Phase 4 Unknown
NCT04961138 2021-07-14
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT03951597 2021-07-07
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04042805 2021-03-02
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04170179 2021-02-23
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Phase 2 Unknown
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT04741165 2021-02-05
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04560751 2020-09-23
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Zhejiang Cancer Hospital
Unknown
NCT04443322 2020-09-22
Dulect2020-1
RenJi Hospital
Phase NA Unknown
NCT04319484 2020-03-24
LLTHVV
RenJi Hospital
Phase 2/3 Unknown
NCT04273100 2020-02-17
PLTHCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04241523 2020-01-27
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04227808 2020-01-14
Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04168944 2019-11-19
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
RenJi Hospital
Phase 2/3 Unknown